Description: This presentation from Session 4PD of the SOA 1996 Orlando Annual Meeting provides an update on the issues addressed and findings reached by the American Academy of Actuaries [AAA] work group responsible for Medical Savings Accounts [MSAs]. From the Record of the Society of Actuaries, Vol. 22, No. 3.

Description: Session 5 of the 1990 Valuation Actuary Symposium is an open forum on the long term health insurance risks. Also discussed is major medical and disability insurances.

Description: This is the second article in a four–part series. In this article, the industry's products are examined.

Description: Panelists at this session of the SOA 1997 Palm Desert Spring Meeting present current developments in both Medicare risk programs and Medicare supplement products.

Description: This paper describes the construction of the 1965 Supplementary Major Medical Tabular used to measure expect4ed claims. The paper also comments on the relationship of the intercompany 1963-65 experience to it. From Transactions of Society of Actuaries 1968, Vol. 20, Pt. 1, No. 56 AB.

Description: This discussion focuses on the effect the introduction of provincial hospital plans in Canada has had on the trend of loss ratios on associated major medical expense plans. The discussion further looks at deductible amounts, coinsurance provisions, and maximum limits used under major medical expense plans. From Transactions of Society of Actuaries 1961, Vol. 13, Pt. 2.

Description: The presenters will provide updates on research being conducted under SOA sponsorship. This includes projects on the topics of Direct Primary Care and Patient Centered Medical Homes.

Description: This is a discussion of the paper, Surgical and Medical Insurance by a Blue Shield Plan by Arthur Hunter and James F. Coleman. From Transactions of Society of Actuaries 1954, Vol. 6, No. 16.

Description: This article attempts to make a modest contribution to the dialogue on the potential and risks associated with novel treatments such as cell & gene therapies. With a fast-expanding roster of what are believed to be one-time treatments at ever increasing price points aimed at curing a wider swatch of the population, they are as much a source of relief for patients stuck in medical limbo, as they are a source of anxiety for payers.